FDA Determines Regulatory Review Period for JARDIANCE Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for JARDIANCE, a human drug product, in accordance with US law, following a patent extension application submitted to the US Patent and Trademark Office (USPTO).